Thomas joined MVM in 2002. Before joining MVM, he qualified as a chartered accountant with PricewaterhouseCoopers’ Private Equity and Venture Capital practice. Thomas has an MBioch in Molecular and Cellular Biochemistry from Oxford University.
Thomas is a member of the boards of Onbone Oy and Patient Connect Ltd. He was previously a director of Xention Pharma, Lombard Medical Technologies plc (NASDAQ:EVAR), Heptares Ltd (acquired by Sosei Group Corporation), Avantium BV and Alliance Pharma plc (AIM:APH).
MVM Partners LLP
30 St George Street